Heinz Rupp

List of Publications by Year
in descending order

74 papers	2,982 citations	159585 30 h-index	161849 54 g-index
76 all docs	76 docs citations	76 times ranked	2303 citing authors

#	Article	IF	Citations
1	Adverse effects of ethyl esters or oxidation products in omega-3 preparations?. Cardiovascular Journal of Africa, 2014, 25, 86-7.	0.4	1
2	Replacement of Reduced Highly Unsaturated Fatty Acids (HUFA Deficiency) in Dilative Heart Failure: Dosage of EPA/DHA and Variability of Adverse Peroxides and Aldehydes in Dietary Supplement Fish Oils. Cardiology, 2013, 125, 223-231.	1.4	11
3	From Sleep-Disordered Breathing to Increased Left Ventricular Wall Stress in Heart Failure. Chest, 2012, 142, 813.	0.8	2
4	Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in â€œHUFA deficiencyâ€. Canadian Journal of Physiology and Pharmacology, 2012, 90, 55-73.	1.4	18
5	Increased enddiastolic wall stress precedes left ventricular hypertrophy in dilative heart failureâ€"Use of the volume-based wall stress index. International Journal of Cardiology, 2012, 157, 233-238.	1.7	54
6	Occurrence of late gadolinium enhancement is associated with increased left ventricular wall stress and mass in patients with nonâ€ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2011, 13, 937-944.	7.1	46
7	Association of hyperhomocysteinemia with left ventricular dilatation and mass in human heart. Clinical Chemistry and Laboratory Medicine, 2010, 48, 555-60.	2.3	20
8	Occurrence of late gadolinium enhancement in ventricular ballooning or Tako-Tsubo syndrome: increased wall stress should not be overlooked. European Heart Journal, 2009, 30, 2948-2949.	2.2	6
9	OmacorÂ® (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Advances in Therapy, 2009, 26, 675-690.	2.9	31
10	N-3 polyunsaturated fatty acids and statins in heart failure. Lancet, The, 2009, 373, 378-379.	13.7	15
11	Assessment and relevance of ventricular wall stress in heart failure. European Heart Journal, 2008, 29, 2316-2316.	2.2	12
12	Separation of large mammalian ventricular myosin differing in ATPase activityThis paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 326-331.	1.4	5
13	Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?. Current Medical Research and Opinion, 2007, 23, S25-S29.	1.9	2
14	Acute Heart Failureâ€"Basic Pathomechanism and New Drug Targets. Herz, 2006, 31, 727-735.	1.1	13
15	Microdetermination of fatty acids by gas chromatography and cardiovascular risk stratification by the "EPA+DHA level". Herz, 2006, 31 Suppl 3, 30-49.	1.1	2
16	Tedisamil attenuates foetal transformation of myosin in the hypertrophied rat myocardium. British Journal of Pharmacology, 2004, 143, 561-572.	5.4	3
17	Risk Stratification by the ?EPA+DHA Level? and the ?EPA/AA Ratio?. Herz, 2004, 29, 673-685.	1.1	58
18	Drug development based on functional genomics of overloaded cardiomyocytes: a novel approach for preventing progression of heart failure. Journal of Muscle Research and Cell Motility, 2004, 25, 608-9.	2.0	0

#	Article	IF	Citations
19	Effects of ACE Inhibition versus Non-ACE Inhibitor Antihypertensive Treatment on Myocardial Fibrosis in Patients with Arterial Hypertension. Herz, 2003, 28, 744-753.	1.1	43
20	Drug Development Based on Functional Genomics of Overloaded Cardiomyocytes: CPT 1 vs. PPARalpha Effects of Etomoxir. Progress in Experimental Cardiology, 2003, , 177-194.	0.0	1
21	The Use of Partial Fatty Acid Oxidation Inhibitors for Metabolic Therapy of Angina Pectoris and Heart Failure. Herz, 2002, 27, 621-636.	1.1	95
22	Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opinion on Investigational Drugs, 2002, 11, 345-356.	4.1	36
23	Heart failure development in rats with ascending aortic constriction and angiotensin-converting enzyme inhibition. British Journal of Pharmacology, 2000, 130, 1671-1677.	5.4	19
24	Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure. British Journal of Pharmacology, 2000, 131, 1748-1756.	5.4	34
25	Title is missing!. , 2000, 212, 219-225.		4
26	Control of cardiomyocyte gene expression as drug target. Molecular and Cellular Biochemistry, 2000, 212, 135-142.	3.1	8
27	Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease. Circulation, 2000, 102, 1388-1393.	1.6	591
28	Control of cardiomyocyte gene expression as drug target. , 2000, , 135-142.		0
29	Alterations of heart function and Na⁺-K⁺-ATPase activity by etomoxir in diabetic rats. Journal of Applied Physiology, 1999, 86, 812-818.	2.5	25
30	Biphasic changes in heart performance with food restriction in rats. Journal of Applied Physiology, 1999, 87, 1909-1913.	2.5	18
31	Subcellular Remodeling and Heart Dysfunction in Cardiac Hypertrophy due to Pressure Overloada. Annals of the New York Academy of Sciences, 1999, 874, 100-110.	3.8	24
32	Excess Catecholamine Syndrome: Pathophysiology and Therapya. Annals of the New York Academy of Sciences, 1999, 881, 430-444.	3.8	18
33	Modification of left ventricular hypertrophy by chronic etomoxir treatment. British Journal of Pharmacology, 1999, 126, 501-507.	5.4	44
34	Control of apoptosis of cardiovascular fibroblasts: A novel drug target. Herz, 1999, 24, 225-231.	1.1	9
35	Transcriptional modulators targeted at fuel metabolism of hypertrophied heart. American Journal of Cardiology, 1999, 83, 31-37.	1.6	33
36	Is a dietary n-3 fatty acid supplement able to influence the cardiac effect of the psychological stress?. Molecular and Cellular Biochemistry, 1998, 178, 353-366.	3.1	30

#	Article	IF	Citations
37	Title is missing!. Molecular and Cellular Biochemistry, 1998, 188, 209-215.	3.1	4
38	Title is missing!. , 1998, 188, 225-233.		7
39	Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan. , 1998, , 225-233.		6
40	Differential influence of fasting and BM13.907 treatment on growth and phenotype of pressure overloaded rat heart. , 1998, , 209-215.		3
41	Renin-angiotensin system and myocardial collagen matrix. Journal of Hypertension, 1997, 15, S13-S19.	0.5	57
42	Regulation and Role of Myocardial Collagen Matrix Remodeling in Hypertensive Heart Disease. Advances in Experimental Medicine and Biology, 1997, 432, 35-44.	1.6	92
43	Etomoxir Improves Left Ventricular Performance of Pressure-Overloaded Rat Heart. Circulation, 1997, 96, 3681-3686.	1.6	96
44	Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB Journal, 1996, 10, 1303-1309.	0.5	73
45	Sympathoadrenergic overactivity and lipid metabolism. Cardiovascular Drugs and Therapy, 1996, 10, 223-230.	2.6	16
46	Mechanisms of alterations in cardiac membrane Ca2+ transport due to excess catecholamines. Cardiovascular Drugs and Therapy, 1996, 10, 231-238.	2.6	59
47	Modification of catecholamine-induced changes in heart function by food restriction in rats. Cardiovascular Drugs and Therapy, 1996, 10, 239-246.	2.6	23
48	Effects of long-term dietary restriction on cardiovascular function and plasma catecholamines in the rat. Cardiovascular Drugs and Therapy, 1996, 10, 247-250.	2.6	28
49	Drug withdrawal and rebound hypertension: Differential action of the central antihypertensive drugs moxonidine and clonidine. Cardiovascular Drugs and Therapy, 1996, 10, 251-262.	2.6	33
50	Dietary linolenic acid-mediated increase in vascular prostacyclin formation. Molecular and Cellular Biochemistry, 1996, 162, 59-64.	3.1	26
51	Gene Expression of Cardiac Myocytes: A Pharmacologic Target for the Failing Heart?. Developments in Cardiovascular Medicine, 1996, , 171-188.	0.1	0
52	Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. American Journal of Cardiology, 1995, 76, 8D-13D.	1.6	93
53	Modification of myosin isozymes and SR Ca2+-pump ATPase of the diabetic rat heart by lipid-lowering interventions. Molecular and Cellular Biochemistry, 1994, 132, 69-80.	3.1	51
54	Paradoxical role of lipid metabolism in heart function and dysfunction. , 1992, 116, 3-9.		16

#	Article	IF	Citations
55	Modification of subcellular organelles in pressureâ€overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor. FASEB Journal, 1992, 6, 2349-2353.	0.5	74
56	Paradoxical role of lipid metabolism in heart function and dysfunction. Molecular and Cellular Biochemistry, 1992, 116, 3-9.	3.1	51
57	Diabetes-like action of intermittent fasting on sarcoplasmic reticulum Ca2+-pump ATPase and myosin isoenzymes can be prevented by sucrose. Biochemical and Biophysical Research Communications, 1989, 164, 319-325.	2.1	30
58	Influence of a diet rich in fish oil on blood pressure, body weight and cardiac hypertrophy in spontaneously hypertensive rats. European Journal of Applied Physiology and Occupational Physiology, 1988, 58, 97-99.	1.2	18
59	Sucrose feeding prevents changes in myosin isoenzymes and sarcoplasmic reticulum Ca2+ -PUMP ATPase in pressure-loaded rat heart. Biochemical and Biophysical Research Communications, 1988, 156, 917-923.	2.1	30
60	Chronic cardiac reactions. IV. Effect of drugs and altered functional loads on cardiac energetics as inferred from myofibrillar ATPase and the myosin isoenzyme population. , 1987, 82 Suppl 2, 173-182.		2
61	Correlation between total catecholamine content and redistribution of myosin isoenzymes in pressure loaded ventricular myocardium of the spontaneously hypertensive rat. , 1986, 81 Suppl 1, 147-155.		4
62	Response of blood pressure and cardiac myosin polymorphism to swimming training in the spontaneously hypertensive rat. Canadian Journal of Physiology and Pharmacology, 1982, 60, 1098-1103.	1.4	72
63	Oxidation-reduction reactions of copper-thiolate centres in Cu-thionein. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1979, 578, 462-475.	1.7	26
64	Copper-Thionein and Other Metal-Sulphur-Proteins. Exs, 1979, 34, 221-230.	1.4	10
65	Structural Aspects and Reduction Oxidation Reactions of Metallothionein. Exs, 1979, 34, 231-240.	1.4	5
66	Circular dichroism of metallothioneins. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 209-226.	1.7	110
67	Reactions of D-penicillamine with copper in Wilson's disease. Biochemical and Biophysical Research Communications, 1976, 72, 223-229.	2.1	23
68	Copper(I) and copper(II) in complexes of biochemical significance studied by X-ray photoelectron spectroscopy. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1976, 446, 151-165.	1.7	45
69	X-ray photoelectron spectroscopy of copper(II), copper(I), and mixed valence systems. Bioinorganic Chemistry, 1976, 6, 45-59.	1.1	57
70	X-ray photoelectron spectroscopy of some selenium containing amino acids. Bioinorganic Chemistry, 1975, 5, 21-32.	1.1	34
71	270 MHz proton magnetic resonance spectra of metallothionein. FEBS Letters, 1974, 40, 176-179.	2.8	29
72	Conversion of metallothionein into Cu-thionein, the possible low molecular weight form of neonatal hepatic mitochondrocuprein. FEBS Letters, 1974, 44, 293-297.	2.8	95

#	Article	IF	Citations
73	Characterization of Cd, Zn-Thionein (Metallothionein) Isolated from Rat and Chicken Liver. FEBS Journal, 1973, 39, 127-140.	0.2	196
74	Cadmium-induced synthesis of hepatic metallothionein in chicken and rats. FEBS Letters, 1973, 32, 171-174.	2.8	55